• Duggett, N. A., & Flatters, S. J. (2017). Characterization of a rat model of bortezomib‐induced painful neuropathy. British journal of pharmacology, 174(24), 4812-4825.
• Yamamoto, S., Kawashiri, T., Higuchi, H., Tsutsumi, K., Ushio, S., Kaname, T., ... & Egashira, N. (2015). Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats. Journal of pharmacological sciences, 129(1), 43-50.
• Moschetti, G., Amodeo, G., Maftei, D., Lattanzi, R., Procacci, P., Sartori, P., ... & Franchi, S. (2019). Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy. Journal of Neuroinflammation, 16(1), 89.
• Xie, J. D., Chen, S. R., Chen, H., & Pan, H. L. (2017). Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord. Neuropharmacology, 123, 477-487.
• Tung, D., Cheung, P. H., Kaur, P., Foreman, O., Kavirayani, A., Hain, H. S., & Saha, S. (2011). Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Pharmacology, 88(1-2), 100-113.